PBH 超出了第三季度的盈利预期，上调了 2026 年的指引，尽管业绩强劲，但股价仍下跌。 PBH beat Q3 earnings estimates, raised 2026 guidance, and shares dipped despite strong results.

Prestige Consumer Healthcare （PBH） 报告称，2025 年第三季度每股收益为 1.07 美元，比预期高出 0.10 美元，收入为 2.7411 亿美元，尽管同比下降 3.4%，但超出预期。 Prestige Consumer Healthcare (PBH) reported Q3 2025 earnings of $1.07 per share, beating estimates by $0.10, and revenue of $274.11 million, exceeding expectations despite a 3.4% year-over-year decline. 该公司将其2026年全年EPS指导意见提高到4.540至4.580美元。 The company raised its 2026 full-year EPS guidance to $4.540–$4.580. 股价收盘时为59.85美元,下跌1.51美元, 持有"共识评级, 目标价为85.33美元. Shares closed at $59.85, down $1.51, with a "Hold" consensus rating and a target price of $85.33. 该公司在北美和国际 OTC 保健机构开展业务,保持了强劲的利润率和流动性。 The firm operates in North American and international OTC healthcare, maintaining strong margins and liquidity.